US20100286023A1 - Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly - Google Patents
Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly Download PDFInfo
- Publication number
- US20100286023A1 US20100286023A1 US12/842,855 US84285510A US2010286023A1 US 20100286023 A1 US20100286023 A1 US 20100286023A1 US 84285510 A US84285510 A US 84285510A US 2010286023 A1 US2010286023 A1 US 2010286023A1
- Authority
- US
- United States
- Prior art keywords
- composition
- muscle
- amino acid
- amino acids
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 210000003205 muscle Anatomy 0.000 title abstract description 62
- 238000000034 method Methods 0.000 title abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 105
- 229960004203 carnitine Drugs 0.000 claims abstract description 10
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 2
- 229940024606 amino acid Drugs 0.000 claims description 94
- 239000003797 essential amino acid Substances 0.000 claims description 90
- 235000020776 essential amino acid Nutrition 0.000 claims description 89
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 54
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 42
- 150000001720 carbohydrates Chemical class 0.000 claims description 42
- 235000018102 proteins Nutrition 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 26
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 22
- 239000004475 Arginine Substances 0.000 claims description 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 20
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 20
- 239000004471 Glycine Substances 0.000 claims description 18
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 17
- 239000004473 Threonine Substances 0.000 claims description 17
- 108010046377 Whey Proteins Proteins 0.000 claims description 17
- 229960000310 isoleucine Drugs 0.000 claims description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- 102000007544 Whey Proteins Human genes 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 14
- -1 phenylanlanine Chemical compound 0.000 claims description 14
- 239000004474 valine Substances 0.000 claims description 14
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 13
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 13
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 13
- 229960003624 creatine Drugs 0.000 claims description 13
- 239000006046 creatine Substances 0.000 claims description 13
- 229930182817 methionine Natural products 0.000 claims description 13
- 235000021119 whey protein Nutrition 0.000 claims description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 230000002641 glycemic effect Effects 0.000 abstract description 14
- 235000001014 amino acid Nutrition 0.000 description 77
- 102000008934 Muscle Proteins Human genes 0.000 description 72
- 108010074084 Muscle Proteins Proteins 0.000 description 72
- 230000014616 translation Effects 0.000 description 70
- 238000001243 protein synthesis Methods 0.000 description 65
- 229960003136 leucine Drugs 0.000 description 39
- 235000014633 carbohydrates Nutrition 0.000 description 31
- 230000000694 effects Effects 0.000 description 25
- 230000004044 response Effects 0.000 description 22
- 230000037406 food intake Effects 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000013589 supplement Substances 0.000 description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- 229960005190 phenylalanine Drugs 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 235000009697 arginine Nutrition 0.000 description 17
- 229960003121 arginine Drugs 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 description 14
- 239000011707 mineral Substances 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 229960002885 histidine Drugs 0.000 description 12
- 229960002898 threonine Drugs 0.000 description 12
- 229960004295 valine Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229960004452 methionine Drugs 0.000 description 11
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
- 235000004279 alanine Nutrition 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- 229940077731 carbohydrate nutrients Drugs 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- 208000001076 sarcopenia Diseases 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229960001456 adenosine triphosphate Drugs 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 230000006362 insulin response pathway Effects 0.000 description 7
- 229960003646 lysine Drugs 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 239000004395 L-leucine Substances 0.000 description 6
- 235000019454 L-leucine Nutrition 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000004220 muscle function Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000037180 bone health Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 229960002449 glycine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000005802 health problem Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000004844 protein turnover Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 3
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 229930182844 L-isoleucine Natural products 0.000 description 3
- 229930195722 L-methionine Natural products 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000011458 pharmacological treatment Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000021075 protein intake Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 230000003161 proteinsynthetic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- ACRRANHJMOPYFZ-UHFFFAOYSA-N 6-methyl-2,2-dioxooxathiazinan-4-one Chemical compound CC1CC(=O)NS(=O)(=O)O1 ACRRANHJMOPYFZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001494501 Prosopis <angiosperm> Species 0.000 description 1
- 235000001560 Prosopis chilensis Nutrition 0.000 description 1
- 235000014460 Prosopis juliflora var juliflora Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241001047198 Scomberomorus semifasciatus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- AJXBTRZGLDTSST-UHFFFAOYSA-N amino 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)ON AJXBTRZGLDTSST-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012179 bayberry wax Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000012467 brownies Nutrition 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention generally relates to compositions and methods for increasing muscle mass, strength, and functional performance in the elderly.
- the compositions consist of a selection of amino acids including leucine, carnitine, and carbohydrates with low glycemic index.
- sarcopenia refers to the loss of muscle mass and function that inevitably occurs with aging. Sarcopenia is responsible for decreased levels of physical activity which, in turn, can result in increased body fat and a further loss of muscle. Loss of muscle mass results from a negative net balance between muscle protein synthesis and muscle protein breakdown. The etiology of this loss of skeletal muscle mass and function is not believed to be clear. Reduced levels of physical activity, loss of motor units secondary to changes in the central nervous system, and inadequate protein intake have all been implicated.
- Sarcopenic individuals in their relatively weaker state, may be more prone to falls and injuries from performing bodily tasks that may have been performed more easily when they had greater muscle mass and function. They also may have decreased bone and joint health, which further limits mobility. Because sarcopenia increases risk of injury, decreases mobility and quality of life, and causes other problems, it is desirable to effectively, noninvasively, and relatively inexpensively prevent or ameliorate sarcopenia and increase muscle mass, strength, and physical function, especially in the elderly.
- Stimulation of muscle protein synthesis is believed to be the metabolic basis for increased muscle strength.
- An increase in muscle protein synthesis can increase muscle mass, which is related to strength.
- Increasing muscle protein synthesis also increases muscle protein turnover (i.e., the combination of protein synthesis and breakdown), since the rate of breakdown is believed to be related to the rate of synthesis to some extent.
- Increased muscle protein turnover increases the functioning of muscle fiber units, because the older, damaged proteins are replaced by newly produced proteins that function more efficiently.
- a method to increase muscle protein synthesis and muscle protein turnover may achieve the goal of increasing muscle mass, strength, and physical function.
- muscle protein synthesis can be increased either pharmacologically or through nutrition.
- Pharmacological interventions e.g., testosterone
- nutritional compositions are desirable because they are noninvasive and may be designed to minimize such side effects, and may become a part of an individual's routine without such medical supervision.
- whey isolates currently comprise between about 6 and about 9% leucine; this is not believed to be sufficient to achieve improved muscle mass, strength, and functional performance in the elderly.
- compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index are disclosed herein.
- compositions of matter for increasing muscle mass, strength, and functional performance comprising leucine, carbohydrate, and creatine.
- compositions of matter for increasing muscle mass, strength, and functional performance comprising leucine, other amino acids, carbohydrate, and creatine; wherein the other amino acids are selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- the other amino acids may comprise histidine, isoleucine, valine, lysine, methionine, phenylanlanine, threonine, glycine and arginine, or histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, glycine and citrullene.
- the carbohydrate comprises ribose.
- the leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably about 11 and about 20 percent.
- such a composition is a component of means for liquid administration.
- composition further comprises an excipient.
- a method of increasing muscle mass, strength, and functional performance comprising: having a patient; and delivering to the patient a composition of matter comprising leucine, carbohydrate, and creatine.
- the patient is elderly and the method of delivering may be oral, such as through liquid administration.
- the composition further comprises other amino acids selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably between about 11 and about 20 percent.
- the composition further comprises an excipient and the carbohydrate comprises ribose.
- a method of increasing muscle mass, strength, and functional performance in the elderly comprising: generating a composition of matter comprising leucine, carbohydrate, and creatine; providing to an elderly patient the composition of matter.
- the composition further comprises other amino acids selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- the leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably between about 11 and about 20 percent.
- the providing is oral, such as by liquid administration.
- the carbohydrate comprises ribose.
- FIG. 1 shows the metabolic pathways for the synthesis of RNA and how ribose and glycine are believed to serve as precursors for the production of new RNA.
- FIG. 2 shows results of infusing subjects with one of three doses of an embodiment of a composition for increasing muscle mass, strength, and functional performance.
- FIG. 3 shows responses of net muscle protein balance to ingestion of an embodiment of a composition for increasing muscle mass, strength, and functional performance.
- FIG. 4 shows a comparison of the effects of two embodiments of compositions for increasing muscle mass, strength, and functional performance on muscle protein anabolism in young and elderly subjects.
- FIG. 5 shows a dose response to an embodiment of a composition for increasing muscle mass, strength, and functional performance in a profile equal to that in whey protein.
- FIG. 6 shows the effect of embodiments of a composition for increasing muscle mass, strength, and functional performance on muscle protein synthesis.
- FIG. 7 shows net phenylalanine uptake after delivery of a composition for increasing muscle mass, strength, and functional performance.
- FIG. 8 shows the effects of an embodiment of a composition for increasing muscle mass, strength, and functional performance on lean body mass and preservation of muscle function.
- FIG. 9 shows muscular shortening velocity and peak power maintained after delivery of an embodiment of a composition for increasing muscle mass, strength, and functional performance.
- FIG. 10 shows a comparison of increase in muscle protein synthesis after ingestion of a single dose of an embodiment of composition for increasing muscle mass, strength, and functional performance with a pharmacological treatment with insulin, testosterone and growth hormone.
- FIG. 11 shows nitrogen flux between liver and muscle during a fasting state.
- FIG. 12 shows nitrogen flux between liver and muscle related to delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance.
- FIG. 13 shows alanine concentration after delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance.
- FIG. 14 shows urea production after delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance.
- Strength and physical function may be improved by increasing muscle mass and function and improving bone and joint health by stimulating muscle protein synthesis.
- compositions and methods that increase muscle protein mass, strength and physical function in those with sarcopenia, including but not limited to the elderly or individuals over 60 years of age.
- the compositions generally consist of a blend of amino acids, including leucine, and carbohydrates in which the proportion of each amino acid and the amount of carbohydrate is tailored to optimize muscle protein synthesis and muscle protein turnover, and consequently increase muscle mass, strength and physical function.
- the compositions may also or alternatively comprise creatine.
- the new composition addresses all the aspects of protein synthesis.
- the eukaryotic initiation factors are activated by the amino acid leucine.
- the availability of the essential amino acids not produced by the body will be increased by ingestion of the composition.
- the non-essential amino acid component of the newly synthesized protein may be derived from available pools resulting from protein breakdown or de novo synthesis.
- the availability of tRNA may be increased by ingestion of ribose and glycine, key precursors for nucleotide synthesis, and stimulation of tRNA synthesis by the ingested amino acids.
- Energy may be provided by low-glycemic carbohydrates that may induce a minimal insulin response. In an embodiment, such energy is provided in the exact amount needed.
- Protein synthesis may be increased by the provision of key amino acid precursors and also by stimulation of the synthesis of transfer-ribonucleic acid (tRNA), which governs a rate-limiting step in protein synthesis. Function will be enhanced by increasing the energy stores within muscle.
- compositions and methods may also minimize the renal burden.
- Ingestion of a high proportion of the essential amino acids not produced in the body i.e., essential amino acids, or EAAs
- EAAs essential amino acids
- Alanine and glutamine will be reincorporated into protein at a greater rate by the provision of essential amino acids, and urea production will not increase, and may actually decrease.
- Renal function may be preserved by minimizing urea production through the suppression of transport of the primary ureagenic amino acids alanine and glutamine to the liver by instead stimulating their reincorporation into protein.
- compositions disclosed herein relate to both the individual effects of the components and their interactive effects.
- the amino acids will stimulate muscle protein synthesis.
- the particular essential amino acids are provided because they cannot be produced in the body and are thus their availability is rate-limiting for protein synthesis.
- Arginine is normally produced in adequate quantities in the body, but endogenous production may be limited in elderly.
- Glycine is also produced in the body, but in limited amounts; it is believed that extra glycine may stimulate synthesis of tRNA as well as collagen in tendons and ligaments.
- Citrullene can be used as a precursor for arginine to increase the plasma arginine level. Cystine and cysteine, as well as other sulfur-containing amino acids, may be excluded in order to avoid detrimental effects on bone health.
- Amino acids may be included in the free form; in combinations of peptides; in combinations of intact protein and free amino acids; in combinations of free amino and peptides; or in combinations of free amino acids, peptides, and proteins. Their delivery method and quantity is such that there is no undue renal burden.
- One or more low glycemic carbohydrates may provide the energy needed to produce the new protein without eliciting a significant insulin response. This energy source may also drive muscle growth more efficiently than food or other protein supplements in order to achieve muscle synthesis without causing users or patients to compensate for increased calorie intake.
- Such compounds which may also be referred to as slow release saccharides, may include complex carbohydrates with long carbon chain lengths, including but not limited to nutriose, sucramalt, isomaltulose, dextrans, maltodextran, and their functional equivalents.
- the elderly are generally resistant to the action of insulin, so avoiding an insulin response by using low glycemic carbohydrate will be advantageous to that population.
- the composition may comprise ribose.
- Ribose may increase the amount of tRNA, which will be useful when combined with increased availability of the rate-limiting amino acids provided in this embodiment.
- the metabolic pathways by which glycine and ribose may stimulate RNA synthesis are shown in FIG. 1 .
- the term “carbohydrate” used herein may refer to all these compounds.
- Low glycemic carbohydrate may comprise about 0-50% by mass.
- Example 10 About two times the carbohydrate as total amino acids may be added, as this will provide the exact amount of energy needed for the stimulation of muscle protein synthesis resulting from the amino acids. An embodiment of such a calculation is disclosed below in Example 10. In a preferred embodiment, about 25, 26, 27, 28, 29, or 30 g of carbohydrate may be added. These embodiments are based on the energy requirement of protein synthesis resulting from the amino acids, and the amount of energy supplied by the carbohydrate. Close matching of these two values yields the minimal amount of carbohydrate for maximal functionality.
- Creatine is believed to increase muscle mass and improves strength by increasing energy stores in the muscle, and therefore may be a component of a composition for increasing muscle mass.
- components i.e., essential amino acids, low glycemic carbohydrates, and creatine
- muscle strength, mass, and physical function will be increased to a greater extent than predicted by the response to any one component.
- One embodiment encompasses a composition comprising L-histidine, L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-arginine, carbohydrate with low glycemic index, and ⁇ -methyl guandino-acetic acid, or creatine.
- Another embodiment encompasses a composition comprising of L-histidine, L-isoleucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-citrullene, carbohydrate with low glycemic index, and creatine.
- the concentration of L-leucine by mass is greater than about 6% of the amino acid component.
- the concentration of L-leucine is between about 10 and about 40%.
- the concentration of L-leucine is between about 10 and about 25%.
- the concentration of L-leucine is between about 11 and about 20%.
- the concentrations of the other amino acids may be in any proportion to optimize muscle protein synthesis.
- Citrullene may range from about 0-10%
- arginine may range from about 0-10%
- carnitine may range from about 0-15% by weight of amino acids.
- the concentration of L-histidine in the composition may be about 9%, 10%, 11%, 12%, or 13% by weight of the amino acids.
- the concentration of L-methionine in the composition may be about 3%, 3.5%, or 4% by mass of the amino acids.
- the concentration of L-phenylalanine in the composition may be about 13%, 14%, 15%, 16%, or 17% of the amino acids by mass.
- the concentration of L-threonine in the composition may be about 13%, 14%, 15%, 16%, or 17% of the amino acids by mass.
- the concentration of L-valine may be between about 10-12% by mass of the amino acids.
- the concentration of L-isoleucine may be about 9%, 10%, 11%, or 13% by mass of the amino acids.
- the concentration of L-lysine in the composition may be about 9%, 19%, 11%, or 12% of the amino acids by mass.
- the L forms of the amino acids are the naturally occurring isomers normally present in the body.
- the following components have the following percentages of the total amino acids by mass: histidine, about 6.4; isoleucine, about 6.2; lysine, about 11.0; methionine, about 2.0; phenylalnine, about 11.0; threonine, about 9.5; tryptophan, about 0.4; valine, about 7.3; glycine, about 3.8; citrullene, arginine, or a combination thereof, about 3.0; and leucine, the remainder. In a further preferred embodiment, these components total to 20 g of total amino acids.
- creatine may comprise about 8.0% of the composition by mass.
- Carbohydrates may comprise about twice the total mass of histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.
- Ribose may comprise about ten percent of those carbohydrates. It is contemplated that food science requirements may require altering the percentages from these values.
- carnitine may range from about 0-10% by mass of the amino acids, and arginine may range from about 0-10% of the amino acids.
- Leucine may range from about 23-30% by mass of the amino acids, and the low glycemic carbohydrate may range from about 0-50% of the total mass.
- the other amino acids may be in proportion to optimize muscle protein synthesis
- citrulline may range from about 0-10% by mass of the amino acids, and arginine may be excluded.
- Carnitine may range from about 0-15% of mass of amino acids
- L-leucine may range from about 18-30% by mass of the amino acids
- the low glycemic carbohydrate may range from 0-50% by mass.
- the great quantity of amino acids delivered in the compositions and methods disclosed herein also increases muscle strength, mass, and physical function. It is believed that greater total amounts or percentages of protein, and greater amounts or percentages of essential amino acids, particularly leucine, will contribute to greater health effects.
- about 20 g of amino acids are delivered, with about 11 to about 20 percent of those 20 g being leucine.
- Suitable minerals may include one or more minerals or mineral sources.
- minerals include, without limitation: chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium.
- Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
- compositions may also optionally comprise vitamins.
- the vitamins may be fat-soluble or water soluble vitamins. Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin.
- the form of the vitamin may include salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of a vitamin, and metabolites of a vitamin.
- the composition may also comprise at least one excipient.
- suitable excipients include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, a coloring agent, and combinations of any of these agents.
- the excipient is a buffering agent.
- suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
- the excipient may comprise a preservative.
- preservatives include antioxidants, such as alpha-tocopherol or ascorbate, and antimicrobials, such as parabens, chlorobutanol, or phenol.
- the excipient may be a binder.
- Suitable binders include starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C 12 -C 18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, polypeptides, oligopeptides, and combinations thereof.
- the excipient may be a lubricant.
- lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil
- the excipient may be a dispersion enhancer.
- Suitable dispersants may include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.
- the excipient may be a disintegrant.
- the disintegrant may be a non-effervescent disintegrant.
- Suitable examples of non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth.
- the disintegrant may be an effervescent disintegrant. Suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
- the excipient may include a flavoring agent.
- Flavoring agents incorporated into the outer layer may be chosen from synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; and combinations thereof.
- these may include cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
- the excipient may include a sweetener.
- the sweetener may be selected from glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like.
- hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
- Suitable color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors or dyes, along with their corresponding lakes, and certain natural and derived colorants, may be suitable for use in certain embodiments.
- the weight fraction of the excipient or combination of excipients in the formulation may be about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2%, or about 1% or less of the total weight of the amino acid composition.
- compositions disclosed herein may be formulated into a variety of forms and administered by a number of different means.
- the compositions may be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques.
- the compounds of the invention are administered orally.
- Solid dosage forms for oral administration may include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules.
- a capsule typically comprises a core material comprising a composition of the invention and a shell wall that encapsulates the core material.
- the core material may be solid, liquid, or an emulsion.
- the shell wall material may comprise soft gelatin, hard gelatin, or a polymer.
- Suitable polymers include, but are not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name “Eudragit”); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer
- Tablets, pills, and the like may be compressed, multiply compressed, multiply layered, and/or coated.
- the coating may be single or multiple.
- the coating material may comprise a polysaccharide or a mixture of saccharides and glycoproteins extracted from a plant, fungus, or microbe.
- Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum.
- the coating material may comprise a protein. Suitable proteins include, but are not limited to, gelatin, casein, collagen, whey proteins, soy proteins, rice protein, and corn proteins.
- the coating material may comprise a fat or oil, and in particular, a high temperature melting fat or oil.
- the fat or oil may be hydrogenated or partially hydrogenated, and preferably is derived from a plant.
- the fat or oil may comprise glycerides, free fatty acids, fatty acid esters, or a mixture thereof.
- the coating material may comprise an edible wax. Edible waxes may be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills may additionally be prepared with enteric coatings.
- powders or granules embodying the compositions disclosed and made obvious herein may be incorporated into a food product.
- the food product may be a drink for oral administration.
- suitable drink include fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid diary product, a shake, and so forth.
- suitable means for oral administration include aqueous and nonaqueous solutions, emulsions, suspensions and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents.
- the food product may also be a solid foodstuff.
- a solid foodstuff include a food bar, a snack bar, a cookie, a brownie, a muffin, a cracker, an ice cream bar, a frozen yogurt bar, and the like.
- compositions of the invention may be utilized in methods to increase muscle mass, strength and physical function.
- the method comprises administering the composition as described above twice per day between meals.
- the amount per dose may be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 g.
- the composition may be administered one day per day, three times per day, or four times per day.
- the composition may also be used in conjunction with exercise.
- the composition may given before or immediately after exercise.
- the selection of the appropriate dose of the composition is important to maximize the effectiveness per gram ingested. Therefore a study was performed to relate the magnitude of stimulation of muscle protein synthesis to the extent of increase of plasma amino acid concentrations. Subjects were infused with one of three doses of amino acids to produce three distinct levels of plasma amino acids. The amino acids may be delivered as AMINOSYN® (a nutrient preparation containing amino acids). The results are highlighted in FIG. 2 , which shows the relation between increase in plasma EAAs and FSR of muscle protein. Plasma EAA concentrations were increased by infusion of a commercially-available solution, Travasol®. Increases plasma EAA concentrations and muscle protein synthesis were all significant as compared to baseline. FSR at 87 and 261 mg/kg/h were significantly higher than at 43 mg/kg/h (P ⁇ 0.05), but not different from each other.
- EAAs plasma essential amino acids
- muscle protein FSR muscle protein FSR
- anabolism refers to the difference between the rates of muscle protein synthesis and breakdown (i.e., net gain or loss of muscle protein).
- BAAs balanced amino acids
- FIG. 3 shows the response of net muscle protein balance to ingestion of about 40 gm of amino acids in the profile of beef protein, or the about 18 g of EAAs contained in the 40 gm mixture. Both formulations significantly improved net muscle protein balance due to a stimulation of muscle protein synthesis. Deletion of the non-essential amino acids did not adversely affect the response.
- Examples 1 and 2 demonstrate that amino acids stimulate muscle protein synthesis, yet a prior study showed that a high protein meal did not enhance myofibrillar protein synthesis in elderly individuals following resistance exercise. The hypothesis that altered sensitivity to the normally anabolic action of insulin impairs the normal interactive effects between glucose and amino acid intake on muscle protein synthesis was reviewed.
- Muscle protein synthesis and breakdown was measured in healthy young (30 ⁇ 3 yr) and elderly (72 ⁇ 1 yr) volunteers in the basal postabsorptive state and during the administration of an amino acid-glucose mixture, using L[ring- 2 H5]phenylalanine infusion, femoral artery and vein catheterization, and muscle biopsies. Basal muscle amino acid turnover was similar in young and elderly subjects. The mixture increased phenylalanine leg delivery and transport into the muscle in both groups. Phenylalanine net balance increased in both groups (young, ⁇ 27 ⁇ 8 to 64 ⁇ 17; elderly, ⁇ 16 ⁇ 4 to 29 ⁇ 7 nmol/(min ⁇ 100 mL); P ⁇ 0.0001, basal vs.
- FIG. 4 shows a comparison of the effects of an amino acid-glucose supplement vs. the same amount of amino acids alone on muscle protein anabolism in young and elderly subjects. Phenylalanine net balance across the leg increased significantly during oral supplementation in all groups.
- FIG. 6 shows the effect of a composition of EAA mixute on muscle protein synthesis.
- the * indicates a significant difference from low leucine in the elderly (p ⁇ 0.05).
- the + indicates a difference from low leucine in the young.
- Muscle protein synthesis was stimulated in anesthetized rabbits when arginine was increased to about 50% of the total mixture of amino acids infused. Muscle protein breakdown was unchanged when arginine was added to the amino acid solution, meaning that net muscle catabolism was virtually completely reversed in these post-absorptive rabbits.
- the arginine effect was comparable to the response to increasing the proportion of leucine to about 50% of the total.
- the mechanism by which arginine activates the initiation of protein synthesis is the same as leucine. Further, arginine is relatively deficient in the elderly. Thus, addition of arginine may work in concert with leucine to activate protein synthesis in elderly.
- Net phenylalanine uptake an indication of net protein balance, was significantly greater for the EAA group compared to the whey group (P ⁇ 0.05; 53 ⁇ 10 mg phe/leg EAA vs 21 ⁇ 5 mg phe/leg whey; FIG. 7 ). Both supplements stimulated muscle protein synthesis (p ⁇ 0.05), but the increase was greatest in the EAA group. Post-prandial fractional synthetic rates of muscle protein were 0.088 ⁇ 0.011% hr ⁇ 1 for the EAA group, and 0.066 ⁇ 0.004% hr ⁇ 1 for the whey group (p ⁇ 0.05).
- EAA essential amino acid
- CRC Clinical Research Center
- the lack of responsiveness to the potential anabolic action of insulin in elderly makes a supplement that elicits a high insulin response undesirable. Nonetheless, there is a need for energy to fuel the protein synthetic response.
- the exact energy cost can be calculated.
- the calculation of the estimated energy expenditure due to stimulation of muscle protein synthesis following EAA ingestion is based on the average leg muscle mass (LMM) of elderly of 6 kg.
- the muscle in one leg represented approximately 20% of the total muscle mass and about 26% of the leg LMM is protein-bound amino acids.
- Previous work had revealed the fractional synthetic rate of muscle protein increased by an average of 0.03/h following the ingestion of 15 grams of EAAs.
- FIG. 11 shows nitrogen flux between liver and muscle during a fasting state.
- a fraction of the amino acids released as a result of protein breakdown are metabolized, with the resultant production of alanine and glutamine.
- alanine and glutamine There is also a net release of EAAs and the other NEAAS into plasma.
- Alanine and glutamine serve as the principal forms in which the nitrogen (N) from the metabolized amino acids is transported back to the liver for eventual incorporation into urea and subsequent excretion.
- FIG. 12 shows nitrogen flux between liver and muscle following EAA ingestion. This results in the stimulation of synthesis. Since NEAAs are required for the synthesis of new protein, the NEAAs released from protein breakdown will be recycled back into protein at a greater rate, meaning that less will be released into plasma. Alanine and glutamine concentrations thus fall; this effect on alanine concentration after ingestion of boluses of 6 gm each of EAAs at time 0 and 60 min. is shown in FIG. 13 . Since alanine and glutamine are the principal precursors of urea production, urea production does not increase following EAA ingestion, as shown in FIG. 14 . This is in contrast to the response to ingestion of intact protein, such as whey protein, whereby increased N intake results in increased production of urea and burden on the kidney for excretion.
- intact protein such as whey protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index.
Description
- This application is a Continuation of U.S. Utility patent application Ser. No. 12/013,269, filed Jan. 11, 2008 and currently pending, the entire disclosure of which is herein incorporated by reference.
- 1. Field of the Invention
- The present invention generally relates to compositions and methods for increasing muscle mass, strength, and functional performance in the elderly. In particular, the compositions consist of a selection of amino acids including leucine, carnitine, and carbohydrates with low glycemic index.
- 2. Description of the Related Art
- As the population ages, and in particular as the “baby boomers” grow into their old age, the health problems associated with aging grow increasingly important. This is particularly true in a health system such as the current one where health care costs are distributed across the population; the increased prevalence of aging-related health problems will result in generally increased costs to all. In addition, reactive health care is more expensive than preventative health care; for example, fixing broken bones or replacing a hip after a fall by a frail patient is more expensive than preventing that fall by decreasing the patient's frailty. For these and other reasons, it is desirable to have effective, relatively inexpensive means for preventing and ameliorating some aging-related health problems.
- One such health problem may be referred to as “sarcopenia.” As used herein, the term “sarcopenia” refers to the loss of muscle mass and function that inevitably occurs with aging. Sarcopenia is responsible for decreased levels of physical activity which, in turn, can result in increased body fat and a further loss of muscle. Loss of muscle mass results from a negative net balance between muscle protein synthesis and muscle protein breakdown. The etiology of this loss of skeletal muscle mass and function is not believed to be clear. Reduced levels of physical activity, loss of motor units secondary to changes in the central nervous system, and inadequate protein intake have all been implicated.
- Sarcopenic individuals, in their relatively weaker state, may be more prone to falls and injuries from performing bodily tasks that may have been performed more easily when they had greater muscle mass and function. They also may have decreased bone and joint health, which further limits mobility. Because sarcopenia increases risk of injury, decreases mobility and quality of life, and causes other problems, it is desirable to effectively, noninvasively, and relatively inexpensively prevent or ameliorate sarcopenia and increase muscle mass, strength, and physical function, especially in the elderly.
- Stimulation of muscle protein synthesis is believed to be the metabolic basis for increased muscle strength. An increase in muscle protein synthesis can increase muscle mass, which is related to strength. Increasing muscle protein synthesis also increases muscle protein turnover (i.e., the combination of protein synthesis and breakdown), since the rate of breakdown is believed to be related to the rate of synthesis to some extent. Increased muscle protein turnover increases the functioning of muscle fiber units, because the older, damaged proteins are replaced by newly produced proteins that function more efficiently. Thus, a method to increase muscle protein synthesis and muscle protein turnover may achieve the goal of increasing muscle mass, strength, and physical function.
- There are believed to be four central components to the stimulation of muscle protein synthesis. The capacity of the synthetic apparatus of the cell must be activated by a series of factors collectively referred to as eukaryotic initiation factors. The availability of all the component amino acids needed for the synthesis of the new proteins must be increased, and transfer RNA (tRNA) molecules must transfer those amino acids effectively from the intracellular free pool to the site of synthesis in the ribosome. Finally, there must be adequate energy available, in the form of adenosine-triphosphate (ATP), for all the necessary reactions to proceed. In sum, increased physical function requires not only adequate muscle mass and function of the muscle fibers, but also the energy needed to support muscle contraction. Energy can be stored in the cell as ATP and creatine-phosphate (CP). Synthesis of ATP is believed to be promoted by the provision of ribose, and creatine is believed to promote the storage of energy in the form of CP.
- By addressing any or all of these four components, muscle protein synthesis can be increased either pharmacologically or through nutrition. Pharmacological interventions (e.g., testosterone) can be effective, but all have significant undesirable side effects and require medical supervision. In contrast, nutritional compositions are desirable because they are noninvasive and may be designed to minimize such side effects, and may become a part of an individual's routine without such medical supervision.
- There are currently no nutritional compositions designed to specifically promote muscle protein synthesis in elderly individuals, or more generally to improve strength and functional performance in elderly individuals. Current nutritional compositions are not believed to have sufficient leucine to effectively accomplish the goals stated herein, alone or in combination with muscle-building compounds such as creatine. For example, whey isolates currently comprise between about 6 and about 9% leucine; this is not believed to be sufficient to achieve improved muscle mass, strength, and functional performance in the elderly.
- A high percentage of elderly individuals suffer some degree of renal insufficiency, often at the sub-clinical (and thus undiagnosed) level. Impaired renal function is common in individuals with sarcopenia, so nutritional approaches to resolving sarcopenia must not compound this potential problem by increasing the load of urea that the kidney must excrete. A high intake of protein could potentially amplify this problem by causing a significant increase in urea production, thereby putting an increased burden on the kidney by requiring increased urinary excretion. It is therefore desirable for any composition for supporting synthesis to minimize renal burden.
- The effect of increased protein intake on bone health has been debated. On the one hand, protein synthesis is essential for bone health and is stimulated by increased protein intake. Since collagen is a major protein component of bone and glycine constitutes about 30% of collagen, it is desirable for a composition promoting bone synthesis to contain sufficient glycine and other amino acids to stimulate collagen synthesis in bone. On the other hand, ingestion of sulphur-containing amino acids, particularly cystine and cysteine, causes the production of sulfuric acid in the course of their metabolism. Increased sulfuric acid acidifies the blood and accelerates loss of calcium from bone. It is therefore desirable for such a composition to circumvent this response by not including either cystine or cysteine, as neither of these amino acids is believed to be necessary for stimulation of muscle protein synthesis.
- An additional difficulty with nutritional supplements for older adults is that older adults generally compensate for increased energy (i.e., calories) delivered by nutritional supplements by reducing food intake. It is therefore desirable to design a supplement that stimulates muscle synthesis more efficiently than food or common protein supplements.
- Because of these and other problems in the art, disclosed herein are compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index.
- There are described herein compositions of matter for increasing muscle mass, strength, and functional performance, comprising leucine, carbohydrate, and creatine.
- There are also described herein compositions of matter for increasing muscle mass, strength, and functional performance, comprising leucine, other amino acids, carbohydrate, and creatine; wherein the other amino acids are selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- In an embodiment of such compositions, the other amino acids may comprise histidine, isoleucine, valine, lysine, methionine, phenylanlanine, threonine, glycine and arginine, or histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, glycine and citrullene.
- In an embodiment of such compositions, the carbohydrate comprises ribose.
- In an embodiment of such compositions, the leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably about 11 and about 20 percent.
- In an embodiment, such a composition is a component of means for liquid administration.
- In a still further embodiment, the composition further comprises an excipient.
- There is also described herein a method of increasing muscle mass, strength, and functional performance, comprising: having a patient; and delivering to the patient a composition of matter comprising leucine, carbohydrate, and creatine.
- In an embodiment of the method the patient is elderly and the method of delivering may be oral, such as through liquid administration.
- In another embodiment of the method, the composition further comprises other amino acids selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- In a still further embodiment of the method, leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably between about 11 and about 20 percent.
- In a still further embodiment of the method, the composition further comprises an excipient and the carbohydrate comprises ribose.
- There is also described herein a method of increasing muscle mass, strength, and functional performance in the elderly, comprising: generating a composition of matter comprising leucine, carbohydrate, and creatine; providing to an elderly patient the composition of matter.
- In an embodiment of the method the composition further comprises other amino acids selected from the group consisting of histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
- In a still further embodiment of the method the leucine comprises a percentage of the composition by mass between about 10 and about 25 percent, more preferably between about 11 and about 20 percent.
- In a still further embodiment of the method the providing is oral, such as by liquid administration.
- In a still further embodiment of the method, the carbohydrate comprises ribose.
-
FIG. 1 shows the metabolic pathways for the synthesis of RNA and how ribose and glycine are believed to serve as precursors for the production of new RNA. -
FIG. 2 shows results of infusing subjects with one of three doses of an embodiment of a composition for increasing muscle mass, strength, and functional performance. -
FIG. 3 shows responses of net muscle protein balance to ingestion of an embodiment of a composition for increasing muscle mass, strength, and functional performance. -
FIG. 4 shows a comparison of the effects of two embodiments of compositions for increasing muscle mass, strength, and functional performance on muscle protein anabolism in young and elderly subjects. -
FIG. 5 shows a dose response to an embodiment of a composition for increasing muscle mass, strength, and functional performance in a profile equal to that in whey protein. -
FIG. 6 shows the effect of embodiments of a composition for increasing muscle mass, strength, and functional performance on muscle protein synthesis. -
FIG. 7 shows net phenylalanine uptake after delivery of a composition for increasing muscle mass, strength, and functional performance. -
FIG. 8 shows the effects of an embodiment of a composition for increasing muscle mass, strength, and functional performance on lean body mass and preservation of muscle function. -
FIG. 9 shows muscular shortening velocity and peak power maintained after delivery of an embodiment of a composition for increasing muscle mass, strength, and functional performance. -
FIG. 10 shows a comparison of increase in muscle protein synthesis after ingestion of a single dose of an embodiment of composition for increasing muscle mass, strength, and functional performance with a pharmacological treatment with insulin, testosterone and growth hormone. -
FIG. 11 shows nitrogen flux between liver and muscle during a fasting state. -
FIG. 12 shows nitrogen flux between liver and muscle related to delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance. -
FIG. 13 shows alanine concentration after delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance. -
FIG. 14 shows urea production after delivery of an embodiment of composition for increasing muscle mass, strength, and functional performance. - Strength and physical function, including mobility, may be improved by increasing muscle mass and function and improving bone and joint health by stimulating muscle protein synthesis. Disclosed herein are compositions and methods that increase muscle protein mass, strength and physical function in those with sarcopenia, including but not limited to the elderly or individuals over 60 years of age. The compositions generally consist of a blend of amino acids, including leucine, and carbohydrates in which the proportion of each amino acid and the amount of carbohydrate is tailored to optimize muscle protein synthesis and muscle protein turnover, and consequently increase muscle mass, strength and physical function. The compositions may also or alternatively comprise creatine.
- Generally, the new composition addresses all the aspects of protein synthesis. The eukaryotic initiation factors are activated by the amino acid leucine. The availability of the essential amino acids not produced by the body will be increased by ingestion of the composition. The non-essential amino acid component of the newly synthesized protein may be derived from available pools resulting from protein breakdown or de novo synthesis. The availability of tRNA may be increased by ingestion of ribose and glycine, key precursors for nucleotide synthesis, and stimulation of tRNA synthesis by the ingested amino acids. Energy may be provided by low-glycemic carbohydrates that may induce a minimal insulin response. In an embodiment, such energy is provided in the exact amount needed. Protein synthesis may be increased by the provision of key amino acid precursors and also by stimulation of the synthesis of transfer-ribonucleic acid (tRNA), which governs a rate-limiting step in protein synthesis. Function will be enhanced by increasing the energy stores within muscle.
- The compositions and methods may also minimize the renal burden. Ingestion of a high proportion of the essential amino acids not produced in the body (i.e., essential amino acids, or EAAs) will cause a diminished availability of alanine and glutamine, the two principal ureagenic amino acids. Alanine and glutamine will be reincorporated into protein at a greater rate by the provision of essential amino acids, and urea production will not increase, and may actually decrease. Renal function may be preserved by minimizing urea production through the suppression of transport of the primary ureagenic amino acids alanine and glutamine to the liver by instead stimulating their reincorporation into protein.
- The rationale underlying the compositions disclosed herein relates to both the individual effects of the components and their interactive effects. The amino acids will stimulate muscle protein synthesis. The particular essential amino acids are provided because they cannot be produced in the body and are thus their availability is rate-limiting for protein synthesis. Arginine is normally produced in adequate quantities in the body, but endogenous production may be limited in elderly. Glycine is also produced in the body, but in limited amounts; it is believed that extra glycine may stimulate synthesis of tRNA as well as collagen in tendons and ligaments. Citrullene can be used as a precursor for arginine to increase the plasma arginine level. Cystine and cysteine, as well as other sulfur-containing amino acids, may be excluded in order to avoid detrimental effects on bone health. Amino acids may be included in the free form; in combinations of peptides; in combinations of intact protein and free amino acids; in combinations of free amino and peptides; or in combinations of free amino acids, peptides, and proteins. Their delivery method and quantity is such that there is no undue renal burden.
- One or more low glycemic carbohydrates may provide the energy needed to produce the new protein without eliciting a significant insulin response. This energy source may also drive muscle growth more efficiently than food or other protein supplements in order to achieve muscle synthesis without causing users or patients to compensate for increased calorie intake. Such compounds, which may also be referred to as slow release saccharides, may include complex carbohydrates with long carbon chain lengths, including but not limited to nutriose, sucramalt, isomaltulose, dextrans, maltodextran, and their functional equivalents. The elderly are generally resistant to the action of insulin, so avoiding an insulin response by using low glycemic carbohydrate will be advantageous to that population.
- In addition to or alternatively to a low glycemic carbohydrate or slow release saccharide, the composition may comprise ribose. Ribose may increase the amount of tRNA, which will be useful when combined with increased availability of the rate-limiting amino acids provided in this embodiment. The metabolic pathways by which glycine and ribose may stimulate RNA synthesis are shown in
FIG. 1 . Because of the similar functionality of low glycemic carbohydrates, slow release saccharides, and ribose in the compositions and methods disclosed herein, the term “carbohydrate” used herein may refer to all these compounds. Low glycemic carbohydrate may comprise about 0-50% by mass. About two times the carbohydrate as total amino acids may be added, as this will provide the exact amount of energy needed for the stimulation of muscle protein synthesis resulting from the amino acids. An embodiment of such a calculation is disclosed below in Example 10. In a preferred embodiment, about 25, 26, 27, 28, 29, or 30 g of carbohydrate may be added. These embodiments are based on the energy requirement of protein synthesis resulting from the amino acids, and the amount of energy supplied by the carbohydrate. Close matching of these two values yields the minimal amount of carbohydrate for maximal functionality. - Creatine is believed to increase muscle mass and improves strength by increasing energy stores in the muscle, and therefore may be a component of a composition for increasing muscle mass. When such components (i.e., essential amino acids, low glycemic carbohydrates, and creatine) are coupled together in a preferred embodiment, muscle strength, mass, and physical function will be increased to a greater extent than predicted by the response to any one component.
- One embodiment encompasses a composition comprising L-histidine, L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-arginine, carbohydrate with low glycemic index, and α-methyl guandino-acetic acid, or creatine.
- Another embodiment encompasses a composition comprising of L-histidine, L-isoleucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-citrullene, carbohydrate with low glycemic index, and creatine.
- As explained, leucine is believed to activate the eukaryotic initiation factors of protein synthesis. In an embodiment, the concentration of L-leucine by mass is greater than about 6% of the amino acid component. In a preferred embodiment the concentration of L-leucine is between about 10 and about 40%. In a more preferred embodiment, the concentration of L-leucine is between about 10 and about 25%. In a most preferred embodiment, the concentration of L-leucine is between about 11 and about 20%.
- The concentrations of the other amino acids may be in any proportion to optimize muscle protein synthesis. Citrullene may range from about 0-10%, arginine may range from about 0-10%, and carnitine may range from about 0-15% by weight of amino acids. The concentration of L-histidine in the composition may be about 9%, 10%, 11%, 12%, or 13% by weight of the amino acids. The concentration of L-methionine in the composition may be about 3%, 3.5%, or 4% by mass of the amino acids. The concentration of L-phenylalanine in the composition may be about 13%, 14%, 15%, 16%, or 17% of the amino acids by mass. The concentration of L-threonine in the composition may be about 13%, 14%, 15%, 16%, or 17% of the amino acids by mass. The concentration of L-valine may be between about 10-12% by mass of the amino acids. The concentration of L-isoleucine may be about 9%, 10%, 11%, or 13% by mass of the amino acids. The concentration of L-lysine in the composition may be about 9%, 19%, 11%, or 12% of the amino acids by mass. The L forms of the amino acids are the naturally occurring isomers normally present in the body.
- In a preferred embodiment, the following components have the following percentages of the total amino acids by mass: histidine, about 6.4; isoleucine, about 6.2; lysine, about 11.0; methionine, about 2.0; phenylalnine, about 11.0; threonine, about 9.5; tryptophan, about 0.4; valine, about 7.3; glycine, about 3.8; citrullene, arginine, or a combination thereof, about 3.0; and leucine, the remainder. In a further preferred embodiment, these components total to 20 g of total amino acids.
- In a further preferred embodiment, creatine may comprise about 8.0% of the composition by mass. Carbohydrates may comprise about twice the total mass of histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Ribose may comprise about ten percent of those carbohydrates. It is contemplated that food science requirements may require altering the percentages from these values.
- In another embodiment carnitine may range from about 0-10% by mass of the amino acids, and arginine may range from about 0-10% of the amino acids. Leucine may range from about 23-30% by mass of the amino acids, and the low glycemic carbohydrate may range from about 0-50% of the total mass. The other amino acids may be in proportion to optimize muscle protein synthesis
- In another embodiment, wherein the taste of the composition may be improved without compromising efficacy, citrulline may range from about 0-10% by mass of the amino acids, and arginine may be excluded. Carnitine may range from about 0-15% of mass of amino acids, L-leucine may range from about 18-30% by mass of the amino acids, and the low glycemic carbohydrate may range from 0-50% by mass.
- In addition to the amino acid selection, the great quantity of amino acids delivered in the compositions and methods disclosed herein also increases muscle strength, mass, and physical function. It is believed that greater total amounts or percentages of protein, and greater amounts or percentages of essential amino acids, particularly leucine, will contribute to greater health effects. In a preferred embodiment, about 20 g of amino acids are delivered, with about 11 to about 20 percent of those 20 g being leucine.
- In alternative or further embodiments, supplemental minerals may also be included. Suitable minerals may include one or more minerals or mineral sources. Non-limiting examples of minerals include, without limitation: chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium. Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
- The compositions may also optionally comprise vitamins. The vitamins may be fat-soluble or water soluble vitamins. Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. The form of the vitamin may include salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of a vitamin, and metabolites of a vitamin.
- The composition may also comprise at least one excipient. Non-limiting examples of suitable excipients include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, a coloring agent, and combinations of any of these agents.
- In an embodiment, the excipient is a buffering agent. Non-limiting examples of suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
- The excipient may comprise a preservative. Suitable examples of preservatives include antioxidants, such as alpha-tocopherol or ascorbate, and antimicrobials, such as parabens, chlorobutanol, or phenol.
- In an alternative or further embodiment, the excipient may be a binder. Suitable binders include starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, polypeptides, oligopeptides, and combinations thereof.
- In an alternative or further embodiment, the excipient may be a lubricant. Suitable non-limiting examples of lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil
- The excipient may be a dispersion enhancer. Suitable dispersants may include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.
- In yet another embodiment, the excipient may be a disintegrant. The disintegrant may be a non-effervescent disintegrant. Suitable examples of non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth. The disintegrant may be an effervescent disintegrant. Suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
- The excipient may include a flavoring agent. Flavoring agents incorporated into the outer layer may be chosen from synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; and combinations thereof. By way of example, these may include cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
- In another embodiment, the excipient may include a sweetener. By way of non-limiting example, the sweetener may be selected from glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like. Also contemplated are hydrogenated starch hydrolysates and the
synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof. - It may be desirable to provide a coloring agent. Suitable color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors or dyes, along with their corresponding lakes, and certain natural and derived colorants, may be suitable for use in certain embodiments.
- The weight fraction of the excipient or combination of excipients in the formulation may be about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2%, or about 1% or less of the total weight of the amino acid composition.
- Also contemplated are methods of delivery of the compositions disclosed herein, including but not limited to dosage. The compositions disclosed or made obvious herein may be formulated into a variety of forms and administered by a number of different means. The compositions may be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. In an exemplary embodiment, the compounds of the invention are administered orally.
- Solid dosage forms for oral administration may include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules. A capsule typically comprises a core material comprising a composition of the invention and a shell wall that encapsulates the core material. The core material may be solid, liquid, or an emulsion. The shell wall material may comprise soft gelatin, hard gelatin, or a polymer. Suitable polymers include, but are not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name “Eudragit”); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers; and shellac (purified lac). Some such polymers may also function as taste-masking agents.
- Tablets, pills, and the like may be compressed, multiply compressed, multiply layered, and/or coated. The coating may be single or multiple. In one embodiment, the coating material may comprise a polysaccharide or a mixture of saccharides and glycoproteins extracted from a plant, fungus, or microbe. Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum. In another embodiment, the coating material may comprise a protein. Suitable proteins include, but are not limited to, gelatin, casein, collagen, whey proteins, soy proteins, rice protein, and corn proteins. In an alternate embodiment, the coating material may comprise a fat or oil, and in particular, a high temperature melting fat or oil. The fat or oil may be hydrogenated or partially hydrogenated, and preferably is derived from a plant. The fat or oil may comprise glycerides, free fatty acids, fatty acid esters, or a mixture thereof. In still another embodiment, the coating material may comprise an edible wax. Edible waxes may be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills may additionally be prepared with enteric coatings.
- Alternatively, powders or granules embodying the compositions disclosed and made obvious herein may be incorporated into a food product. In a preferred embodiment, the food product may be a drink for oral administration. Non-limiting examples of a suitable drink include fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid diary product, a shake, and so forth. Other suitable means for oral administration include aqueous and nonaqueous solutions, emulsions, suspensions and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents.
- The food product may also be a solid foodstuff. Suitable examples of a solid foodstuff include a food bar, a snack bar, a cookie, a brownie, a muffin, a cracker, an ice cream bar, a frozen yogurt bar, and the like.
- The compositions of the invention may be utilized in methods to increase muscle mass, strength and physical function. In an embodiment, the method comprises administering the composition as described above twice per day between meals. The amount per dose may be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 g. Alternatively, the composition may be administered one day per day, three times per day, or four times per day.
- In an alternative or further embodiment of a method of delivery, the composition may also be used in conjunction with exercise. For example, the composition may given before or immediately after exercise.
- The following examples provide embodiments of compositions, their use, and the effects of such use.
- The selection of the appropriate dose of the composition is important to maximize the effectiveness per gram ingested. Therefore a study was performed to relate the magnitude of stimulation of muscle protein synthesis to the extent of increase of plasma amino acid concentrations. Subjects were infused with one of three doses of amino acids to produce three distinct levels of plasma amino acids. The amino acids may be delivered as AMINOSYN® (a nutrient preparation containing amino acids). The results are highlighted in
FIG. 2 , which shows the relation between increase in plasma EAAs and FSR of muscle protein. Plasma EAA concentrations were increased by infusion of a commercially-available solution, Travasol®. Increases plasma EAA concentrations and muscle protein synthesis were all significant as compared to baseline. FSR at 87 and 261 mg/kg/h were significantly higher than at 43 mg/kg/h (P<0.05), but not different from each other. - When plasma essential amino acids (leucine, isoleucine, valine, histidine, lysine, metionine, threonine, phenylalanine) (EAAs) were increased by either about 35% or about 60%, there were proportionate increases in muscle protein FSR. However, when plasma EAAs were increased more than about 300%, muscle protein synthesis increased only slightly more. The relation between plasma EAA concentrations and muscle protein FSR was used to develop the dosage of EAAs in the proposed composition.
- The relative role of essential and non-essential amino acids on the stimulation of muscle protein anabolism in older adults was reviewed. In this case anabolism refers to the difference between the rates of muscle protein synthesis and breakdown (i.e., net gain or loss of muscle protein). The response of muscle protein metabolism to a composition embodiment with about 18 g of essential amino acids (EAAs) was compared to the response to a composition embodiment with about 40 g of balanced amino acids (BAAs) (about 18 g EAA+about 22 g non-essential amino acids, NEAA) given orally to healthy older volunteers (BAA: n=8, age 71±2 yr; EAA: n=6, age 69±2 yr) (35) (
FIG. 3 ). The amino acids were in the profile found in beef protein.FIG. 3 shows the response of net muscle protein balance to ingestion of about 40 gm of amino acids in the profile of beef protein, or the about 18 g of EAAs contained in the 40 gm mixture. Both formulations significantly improved net muscle protein balance due to a stimulation of muscle protein synthesis. Deletion of the non-essential amino acids did not adversely affect the response. - It was determined that phenylalanine net balance across the leg (corresponding to net muscle protein synthesis, or the balance between protein synthesis and breakdown) increased similarly from basal (p<0.01) in both groups (BAA: −16±5 to 16±4; EAA: −18±5 to 14±13; nmol·min−1·100 ml leg−1) due to a similar increase (p<0.01) in muscle protein synthesis (BAA: 43±11 to 67±11; EAA: 62±6 to 75±10; nmol·min−1·100 ml leg−1) and no change in breakdown. In a separate example, ingestion of only non-essential amino acids (NEAAs) had no effect on muscle protein synthesis.
- It was concluded that essential amino acids are solely responsible for the amino acid-induced stimulation of muscle protein anabolism in the elderly. Non-essential amino acids may therefore be withheld from nutritional supplements for sarcopenia. This observation provides the basis for an EAA-based supplement that is more efficient than normal food intake in terms of stimulation of muscle protein synthesis (see Example 4).
- Examples 1 and 2 demonstrate that amino acids stimulate muscle protein synthesis, yet a prior study showed that a high protein meal did not enhance myofibrillar protein synthesis in elderly individuals following resistance exercise. The hypothesis that altered sensitivity to the normally anabolic action of insulin impairs the normal interactive effects between glucose and amino acid intake on muscle protein synthesis was reviewed.
- Muscle protein synthesis and breakdown was measured in healthy young (30±3 yr) and elderly (72±1 yr) volunteers in the basal postabsorptive state and during the administration of an amino acid-glucose mixture, using L[ring-2H5]phenylalanine infusion, femoral artery and vein catheterization, and muscle biopsies. Basal muscle amino acid turnover was similar in young and elderly subjects. The mixture increased phenylalanine leg delivery and transport into the muscle in both groups. Phenylalanine net balance increased in both groups (young, −27±8 to 64±17; elderly, −16±4 to 29±7 nmol/(min·100 mL); P<0.0001, basal vs. mixture), but the increase was significantly blunted in the elderly (P=0.030 vs. young). Muscle protein synthesis increased in the young, but remained unchanged in the elderly [young, 61±17 to 133±30 (P=0.005); elderly, 62±9 to 70±14 nmol/(min·100 mL) (P=S)]. In both groups, protein breakdown decreased (P=0.012) and leg glucose uptake increased (P=0.0258) with the mixture (
FIG. 4 ).FIG. 4 shows a comparison of the effects of an amino acid-glucose supplement vs. the same amount of amino acids alone on muscle protein anabolism in young and elderly subjects. Phenylalanine net balance across the leg increased significantly during oral supplementation in all groups. However, compared with amino acids alone the addition of glucose to the supplement induced a significantly higher response in the young, whereas it did not add any benefit in the elderly. Values are the mean±SE. *, P<0.01 vs. basal; §, P<0.05 vs. others. - It was concluded that the response of muscle protein anabolism is impaired in healthy elderly individuals by a concomitant insulin response to carbohydrate intake. The practical implication of this result is that a dietary supplement to promote muscle protein synthesis in the elderly should not induce an insulin response. It is for this reason that a low glycemic carbohydrate may be used to provide energy and taste while eliciting a minimal insulin response.
- Young and elderly (age>65 years) subjects were given either about 7 gm or about 15 gm of EAAs in an embodiment replicating the proportionate contribution of each EAA to the overall content of whey protein. In response to the 7 gm dose, the elderly had a diminished response, with the total rate of synthesis increasing only half as much as in the young. However, the response to 15 g was equivalent in the two groups, as seen in
FIG. 5 which shows a dose response to essential amino acids in profile equal to that in whey protein. These results underscore the importance of providing an adequate dose to elicit a robust response in the elderly. The observation was explored in more depth in the following examples. - It was hypothesized that there are two components of the mechanism of stimulation of muscle protein synthesis by EAAs: 1) activation of factors involved in the initiation of protein synthesis; and 2) increased availability of precursors. The results presented in
FIG. 6 suggest that the responsiveness of the signaling pathways that ultimately activate the initiation of protein synthesis was blunted in the elderly since precursor availability was increased similarly in both young and old.FIG. 6 shows the effect of a composition of EAA mixute on muscle protein synthesis. The dosage was about 7 gm of each mixture; low leucine=26% leucine; high leucine=40% leucine. The * indicates a significant difference from low leucine in the elderly (p<0.05). The + indicates a difference from low leucine in the young. Consequently, the effect of adjusting the composition of the EAA mixture was tested. It was postulated that increasing the proportion of leucine would activate the initiation pathways, so the proportionate contribution of leucine to the total mixture of amino acids was increased from 8 (the proportion in whey protein) to 40 percent. The results are shown inFIG. 7 , which shows net phenylalanine uptake (reflecting protein synthesis) 3.5 hours after 15 g EAA (N=7) or 15 g of whey (N=8) in elderly subjects. The * indicates P<0.05 as compared to whey protein, though both increases are significantly greater than fasting uptake. - These results indicate that extra leucine is of no particular benefit in younger subjects. Presumably any benefit in terms of more extensive activation of the initiation process was balanced by the diminished supply of the other EAAs as precursors. In contrast, the principal limiting factor in the elderly was apparently activation of initiation, since the high leucine mixture effective increased the response to about 7 g of EAAs to the same as in the young.
- Muscle protein synthesis was stimulated in anesthetized rabbits when arginine was increased to about 50% of the total mixture of amino acids infused. Muscle protein breakdown was unchanged when arginine was added to the amino acid solution, meaning that net muscle catabolism was virtually completely reversed in these post-absorptive rabbits. The arginine effect was comparable to the response to increasing the proportion of leucine to about 50% of the total. The mechanism by which arginine activates the initiation of protein synthesis is the same as leucine. Further, arginine is relatively deficient in the elderly. Thus, addition of arginine may work in concert with leucine to activate protein synthesis in elderly.
- If supplementation entails a nutritional tradeoff of calories, then the supplement must be capable of stimulating net muscle protein synthesis to a greater extent than conventional intake alone. For this reason, the acute response of net muscle protein synthesis (reflected by net phenylalanine uptake) of elderly volunteers to about 15 g EAA supplementation (N=7; 67±2 yrs) and about 15 g of high-quality intact protein (whey; N=8; 69±2 yrs) was reviewed.
- Net phenylalanine uptake, an indication of net protein balance, was significantly greater for the EAA group compared to the whey group (P<0.05; 53±10 mg phe/leg EAA vs 21±5 mg phe/leg whey;
FIG. 7 ). Both supplements stimulated muscle protein synthesis (p<0.05), but the increase was greatest in the EAA group. Post-prandial fractional synthetic rates of muscle protein were 0.088±0.011% hr−1 for the EAA group, and 0.066±0.004% hr−1 for the whey group (p<0.05). The conversion of phenylalanine uptake to mg of protein as described above results in an accrual of 4.0±0.4 g of protein/leg for the EAA supplement, versus 2.2±0.3 g protein/leg for the whey protein, indicating that a 15 g EAA supplement provides a much greater anabolic stimulus than whey protein. Not only was the EAA mixture more effective, but the efficiency of protein utilization (net protein synthesis/protein [i.e., AA] ingestion) was approximately 1.1 for the EAA mixture as opposed to approximately 0.2 for whey protein. The four-fold higher ratio for the EAAs reflects an efficient reutilization of non-essential amino acids that otherwise would have been excreted. This ratio also reflects the optimal formulation of an EAA mixture to match the requirement for muscle protein synthesis. In addition to supporting the general hypothesis underlying this proposal, these results show that the principal effect of exogenous AAs is on muscle protein synthesis as opposed to breakdown. Thus, ingestion of an EAA supplement between meals may reduce periods of post-prandial catabolism and provide frequent stimulation of muscle protein synthesis. - Since muscle protein synthesis decreases with inactivity, we proposed that EAA could restore the synthetic capacity of muscle during bed rest. The hypothesis was that repeated nutritional stimulation of skeletal-muscle protein synthesis throughout 28 days of bed rest would ameliorate the loss of LBM and preserve muscle function. One group of young, healthy volunteers (n=7) received a supplement of about 15 g of EAAs plus about 30 g glucose three times each day, while the other group (n=6) received a placebo drink. The results indicated that the EAA drink was capable of stimulating net muscle protein synthesis throughout the 28 days of inactivity. In comparison, ingestion of a conventional meal replacement drink clinical meal (Boost) was minimally effective in stimulating muscle anabolism, especially after inactivity. The peak response of muscle net balance to the EAA plus glucose supplement was almost six-fold greater than the response to Boost. The repeated stimulation of muscle protein synthesis translated to maintenance of LBM (
FIG. 8A ). Further, preservation of LBM ameliorates the loss of muscle function (FIG. 8B ) with prolonged bed rest. The placebo group's muscle mass of both legs (estimated by dual-energy x-ray absorptiometry [DEXA] analysis) decreased significantly (approximately 438±135 g per 28 days;FIG. 8A ). In contrast, the leg muscle mass demonstrated a non-significant increase of 210±125 g in the supplemental trial, meaning a difference from one trial to the other of approximately 650 g muscle/28 days. Thus,FIG. 8 shows that an essential amino acid (EAA) supplement maintains lean body mass (by DEXA, Panel A) after 28 days of bed rest in 7 subjects (P<0.05). Muscle function is preserved to a greater extent (Panel B) in the EAA group compared to the placebo group (N=6; P<0.05). - The effect of EAA+glucose was also evident at the single fiber level. After 28 d of supplementation in 7 subjects, the EAA+glucose supplement prevented the bed rest-induced depression of peak power and shortening velocity in the fast type II fiber (
FIG. 9 ).FIG. 9 shows shortening velocity (fiber length (FL)/sec; P<0.01) and peak power (μN/FL/sec; P0.05) are maintained in subjects given an EAA supplement (N=7) versus placebo (N=6). While the placebo group demonstrated a decrease in single fiber peak power from pre bed rest (57.6±2.5 vs 69.5±3.5 μN/fiber length (FL)/sec; P<0.05), peak power was maintained in the EAA group (63.9±3.9 μN/FL/sec). Further, shortening velocity was maintained at pre-bed rest levels in the EAA group (0.346±0.015 FL/sec vs 0.323±0.013 FL/sec pre-bed rest; P<0.01). Thus, this data indicates that EAA maintains muscle function at the single fiber level, and that this translates to an increase in function at the whole-muscle level. - These findings highlight two important points. First, supplementation with EAAs+glucose in young, healthy volunteers ameliorated the loss of muscle mass resulting from prolonged inactivity. Second, the repetitive stimulation of muscle protein turner by the dietary supplement resulted in improvement in muscle function at the single fiber level, which translated to an amelioration of the loss of strength at the physiological level.
- Twelve individuals over the age of 62 were given embodiments of essential amino acid supplements twice per day for 8 weeks. The composition of the supplement is shown in Table 1.
-
TABLE 1 Composition of the EAA Supplement. Amino acid Amount (g) % Total Histidine 1.64 10.88 Isoleucine 1.56 10.34 Leucine 2.79 18.50 Lysine 2.30 15.25 Methionine 0.46 3.05 Phenylalanine 2.30 15.25 Threonine 2.20 14.59 Tryptophan 0.10 0.66 Valine 1.73 11.47 Total 15.08 g 100.00 - Subjects (n=12) were greater than 62 years (mean=65.6±2.8). Five of the subjects were male and five were female. On the basis of the dietary and activity records, which were kept throughout, two subjects were dropped. In one case the dietary protein intake changed by approximately 40%, and in the other case the activity level changed drastically as the subject began an organized exercise program.
- After initial screening and acceptance into the study, subjects reported to the Clinical Research Center (CRC) for pretesting. They were then given the supplement dosages in pre-packaged form. They were instructed to take the capsules between breakfast and lunch and between lunch and dinner, and to return the empty single-dose containers, along with a log book documenting when they took the capsules. The subjects reported back to the CRC at 4 weeks and 8 weeks for retesting.
- Regarding compliance, subjects had no problems ingesting the capsules. However, two subjects did not comply with instructions to maintain constant dietary intake (1 subject) or activity level (1 subject), and were subsequently dropped from the study. Thus compliance was 83%.
- Regarding lean body mass, total lean body mass increased in all subjects, the average increase being 1.4±0.3 Kg (mean±SEM) (p=0.025). Similarly, leg lean mass also increased on average of 0.5±0.01 Kg (p=0.0045). There was no discernable effect of initial lean mass or gender on the magnitude of response.
- Regarding leg strength, the overall average (all subjects) leg strength increased from 134.3±21.8 at baseline to 149.9±19.9 (mean±SEM) (p=0.0076).
- A variety of function tests were performed. The subjects were not screened to be frail. As a result, performance on some of the tests was close to maximum before the study started. For example, scores on the Short Physical Performance Battery (SPPB) test averaged 11.6±0.3 (mean±SEM) before the start of the study. Since the maximum value is 12, there was insufficient room for improvement to expect any treatment effect. Significant positive effects of EAA supplementation were observed on function tests in which there were no maximum values. There was an increase in walking speed after EAA supplementation of 0.12±0.015 m/s (mean±SEM) from the basal value of 1.26±0.015 m/s (mean±SEM) (p=0.002).
- In all cases in which statistically significant effects of EAA supplementation were observed, there was a significant correlation between the starting value and the magnitude of impact of the treatment. For example, the weaker the subject at the start of the study, the greater the gain in strength with EAAs, etc.
- It was therefore concluded that supplementation of normal dietary intake with two doses of 11 g of essential amino acids increased muscle mass, strength, and physical function in healthy elderly subjects.
- The lack of responsiveness to the potential anabolic action of insulin in elderly makes a supplement that elicits a high insulin response undesirable. Nonetheless, there is a need for energy to fuel the protein synthetic response. The exact energy cost can be calculated. The calculation of the estimated energy expenditure due to stimulation of muscle protein synthesis following EAA ingestion is based on the average leg muscle mass (LMM) of elderly of 6 kg. The muscle in one leg represented approximately 20% of the total muscle mass and about 26% of the leg LMM is protein-bound amino acids. To calculate the total rate of muscle protein synthesis, previous work had revealed the fractional synthetic rate of muscle protein increased by an average of 0.03/h following the ingestion of 15 grams of EAAs. To calculate the energy cost of muscle protein synthesis, it was assumed that (1) on
average 1 mole of amino acids (AA)=150 g of AA; (2) the cost of synthesizing 1 mol of AA equals 4 ATP; and (3) the hydrolysis of 1 mol of ATP releases 20 Kcal of energy. The formulae are expressed as: -
Total bound AA content of muscle(gm)=Leg LMM(grams)×5×0.26 (1) -
Incorporation of AAs into muscle protein(gm/h)=(1)×FSR(1/h) (2) -
Energy cost of stimulated muscle protein synthesis(Kcal/h)=2×1 mol protein-bound amino acids/150 g muscle×4 mol ATP/mol protein-bound amino acids×20 Kcal/mol ATP (3) - These calculations indicate that the protein synthetic response to EAAs requires about 108 Kcal of energy. This amount of energy can be provided in approximately 27 g of carbohydrate.
- A variety of studies have employed pharmacological treatments increase muscle mass and strength in the elderly. The most potent have been the hormone testosterone (in men), growth hormone, and insulin. The insulin effect was the only one in the same range of effectiveness as EAAs. However, the results with insulin were in a very tightly controlled laboratory setting in which glucose was infused simultaneously to maintain euglycemia. This approach is not practical in a free-living setting, so the relevant comparisons are between EAAs and testosterone and growth hormone. The EAA effect is the largest, as shown in
FIG. 10 , which shows a comparison of increase in muscle protein synthesis after ingestion of a single dose of 15 g of EAAs with the pharmacological treatment with insulin, testosterone and growth hormone. - While the invention has been disclosed in connection with certain preferred embodiments, this should not be taken as a limitation to all of the provided details. Modifications and variations of the described embodiments may be made without departing from the spirit and scope of the invention, and other embodiments should be understood to be encompassed in the present disclosure as would be understood by those of ordinary skill in the art.
- In the fasting situation there is a constant cycling of both EAAs and non-essential amino acids (NEAAs) from protein into the intracellular free amino acid pool and back into protein.
FIG. 11 shows nitrogen flux between liver and muscle during a fasting state. However, a fraction of the amino acids released as a result of protein breakdown are metabolized, with the resultant production of alanine and glutamine. There is also a net release of EAAs and the other NEAAS into plasma. Alanine and glutamine serve as the principal forms in which the nitrogen (N) from the metabolized amino acids is transported back to the liver for eventual incorporation into urea and subsequent excretion. - Following ingestion of EAAs the situation is altered by the net uptake of EAAs.
FIG. 12 shows nitrogen flux between liver and muscle following EAA ingestion. This results in the stimulation of synthesis. Since NEAAs are required for the synthesis of new protein, the NEAAs released from protein breakdown will be recycled back into protein at a greater rate, meaning that less will be released into plasma. Alanine and glutamine concentrations thus fall; this effect on alanine concentration after ingestion of boluses of 6 gm each of EAAs attime FIG. 13 . Since alanine and glutamine are the principal precursors of urea production, urea production does not increase following EAA ingestion, as shown inFIG. 14 . This is in contrast to the response to ingestion of intact protein, such as whey protein, whereby increased N intake results in increased production of urea and burden on the kidney for excretion.
Claims (21)
1. A composition of matter comprising:
an amino acid component, said amino acid component including:
at least 11 percent by mass leucine; and
at least one other essential amino acid; and
a carbohydrate component.
2. The composition of claim 1 wherein said amino acid component comprises: leucine histidine, isoleucine, valine, lysine, methionine, phenylanlanine, threonine, glycine and arginine.
3. The composition of claim 1 wherein said amino acid component comprises: leucine histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, glycine and citrullene.
4. The composition of claim 1 wherein said carbohydrate component comprises about twice the total mass of the amino acid component
5. The composition of claim 4 wherein said carbohydrate component includes ribose.
6. The composition of claim 5 wherein said ribose comprises about 10 percent of said carbohydrate component.
7. The composition of claim 1 wherein said leucine comprises a percentage of said amino acid component by mass less than 40 percent.
8. The composition of claim 7 wherein said leucine comprises a percentage of said amino acid component by mass less than 25 percent.
9. The composition of claim 8 wherein said leucine comprises a percentage of said amino acid component by mass less than 20 percent.
10. The composition of claim 1 further comprising creatine.
11. The composition of claim 1 wherein said composition is placed in a liquid.
12. The composition of claim 11 wherein said liquid comprises a fruit juice.
13. The composition of claim 1 wherein said amino acid component includes intact protein.
14. A composition of matter comprising:
an amino acid component, said amino acid component including:
leucine in an amount above that occurring in whey protein; and
at least one other amino acid; and
a carbohydrate component.
15. The composition of claim 14 wherein at least one of said at least one other amino acid is selected from the group consisting of: histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, arginine, glycine, carnitine, and citrullene.
16. The composition of claim 14 wherein said amino acid component comprises: leucine histidine, isoleucine, valine, lysine, methionine, phenylanlanine, threonine, glycine and arginine.
17. The composition of claim 14 wherein said amino acid component comprises: leucine histidine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, glycine and citrullene.
18. The composition of claim 14 wherein said carbohydrate component comprises about twice the total mass of the amino acid component
19. The composition of claim 14 wherein said composition is placed in a liquid.
20. The composition of claim 19 wherein said liquid comprises a fruit juice.
21. The composition of claim 14 wherein said amino acid component includes intact protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/842,855 US20100286023A1 (en) | 2008-01-11 | 2010-07-23 | Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/013,269 US7790688B2 (en) | 2008-01-11 | 2008-01-11 | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
US12/842,855 US20100286023A1 (en) | 2008-01-11 | 2010-07-23 | Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/013,269 Continuation US7790688B2 (en) | 2008-01-11 | 2008-01-11 | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100286023A1 true US20100286023A1 (en) | 2010-11-11 |
Family
ID=40851201
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/013,269 Expired - Fee Related US7790688B2 (en) | 2008-01-11 | 2008-01-11 | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
US12/842,855 Abandoned US20100286023A1 (en) | 2008-01-11 | 2010-07-23 | Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/013,269 Expired - Fee Related US7790688B2 (en) | 2008-01-11 | 2008-01-11 | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
Country Status (7)
Country | Link |
---|---|
US (2) | US7790688B2 (en) |
EP (1) | EP2231141A2 (en) |
JP (1) | JP2011509293A (en) |
AU (1) | AU2008346842A1 (en) |
CA (1) | CA2711809A1 (en) |
MX (1) | MX2010007580A (en) |
WO (1) | WO2009088738A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090203606A1 (en) * | 2008-02-05 | 2009-08-13 | Wolfe Robert R | Systems for and Methods of use of Therapeutic Nutrition for the Management of Age-Associated and Age-Specific Health Conditions of the Elderly |
US8809259B2 (en) | 2012-03-26 | 2014-08-19 | Pronutria, Inc. | Charged nutritive proteins and methods |
WO2014138304A1 (en) * | 2013-03-08 | 2014-09-12 | Axiom Foods, Inc., | Rice protein supplements |
US9598474B2 (en) | 2012-03-26 | 2017-03-21 | Axcella Health, Inc. | Nutritive fragments, proteins and methods |
US9605040B2 (en) | 2012-03-26 | 2017-03-28 | Axcella Health Inc. | Nutritive proteins and methods |
US9700071B2 (en) | 2012-03-26 | 2017-07-11 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
US11357824B2 (en) | 2013-09-25 | 2022-06-14 | Axcella Health Inc. | Nutritive polypeptides and formulations thereof, and methods of production and use thereof |
US11684074B2 (en) | 2017-05-12 | 2023-06-27 | Axiom Foods, Inc. | Rice products and systems and methods for making thereof |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2631647A1 (en) * | 2005-11-30 | 2007-06-07 | Nestec S.A. | Use of branched-chain amino acids for the treatment of muscle loss |
US8703719B1 (en) * | 2009-05-18 | 2014-04-22 | Bio-Engineered Supplements And Nutrition, Inc. | Method and composition for improved muscle performance |
WO2012024611A1 (en) * | 2010-08-20 | 2012-02-23 | Natural Alternatives International, Inc. | Methods of treating sarcopenia and frailty |
US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
EP2705844B1 (en) * | 2011-04-13 | 2019-05-22 | Ajinomoto Co., Inc. | Nutritional composition |
WO2014045065A2 (en) * | 2012-09-22 | 2014-03-27 | Bslim Holdings Limited | Dietary compositions and their uses |
US9597367B2 (en) * | 2013-04-19 | 2017-03-21 | Bioventures, Llc | Methods for improving muscle and heart function |
EP3115047B1 (en) | 2014-03-07 | 2020-05-06 | Ajinomoto Co., Inc. | Debility preventative |
BR112017005762B1 (en) * | 2014-10-14 | 2021-10-05 | Société des Produits Nestlé S.A. | COMPOSITION INCLUDING A SOURCE OF PROTEIN, AND AN ANTIOXIDANT AND ITS USE |
EP3345595B1 (en) * | 2015-09-04 | 2020-04-08 | University of Tsukuba | Composition for muscle building and method for building muscle |
US10674746B2 (en) | 2015-10-27 | 2020-06-09 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
CN108473384A (en) | 2015-10-27 | 2018-08-31 | 细胞酶动物营养品公司 | Animal nutrition ingredient and correlation technique |
US10888571B2 (en) | 2015-12-18 | 2021-01-12 | Lonza Consumer Health Inc. | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals |
JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
CU20200012A7 (en) | 2017-08-14 | 2021-02-04 | Axcella Health Inc | AMINO ACID COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASE |
US11273138B2 (en) | 2017-11-02 | 2022-03-15 | Bioventures, Llc | Use of amino acid supplementation for improved muscle protein synthesis |
JP2021527670A (en) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US20210260039A1 (en) * | 2018-07-20 | 2021-08-26 | Mend Nutrition Inc. | Nutritional compositions for enhancement of muscle performance |
US11241399B2 (en) * | 2019-04-12 | 2022-02-08 | The Amino Company LLC | Composition for stimulating muscle growth, repair, and maintenance |
AU2021249461A1 (en) * | 2020-04-01 | 2022-08-25 | Société des Produits Nestlé S.A. | Compositions containing amino acids and methods of using such compositions for treating sarcopenia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248771A1 (en) * | 2001-11-01 | 2004-12-09 | Giuseppe Raggi | Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028107A (en) * | 1997-02-27 | 2000-02-22 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US5955102A (en) | 1998-09-04 | 1999-09-21 | Amway Corporation | Softgel capsule containing DHA and antioxidants |
AU2001229672A1 (en) | 2000-01-20 | 2001-07-31 | Bioenergy Inc. | Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans |
US20050002992A1 (en) | 2003-06-17 | 2005-01-06 | Mccleary Edward Larry | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
US7790670B2 (en) | 2002-03-01 | 2010-09-07 | Glanbia Nutritionals (Ireland) Ltd. | Compositions and methods for treatment of body weight conditions |
US20060270739A1 (en) | 2005-04-28 | 2006-11-30 | Trustees Of Tufts College | Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation |
WO2006116755A2 (en) | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
EP1904070A4 (en) | 2005-07-07 | 2009-09-02 | H3 Formulations Ltd | Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
UY30227A1 (en) | 2006-03-20 | 2007-10-31 | Glanbia Nutritionals Ireland Ltd | COMPOSITIONS AND METHODS TO INCREASE VASODILATATION |
-
2008
- 2008-01-11 US US12/013,269 patent/US7790688B2/en not_active Expired - Fee Related
- 2008-12-22 JP JP2010542243A patent/JP2011509293A/en active Pending
- 2008-12-22 EP EP08870082A patent/EP2231141A2/en not_active Withdrawn
- 2008-12-22 CA CA2711809A patent/CA2711809A1/en not_active Abandoned
- 2008-12-22 MX MX2010007580A patent/MX2010007580A/en active IP Right Grant
- 2008-12-22 WO PCT/US2008/087956 patent/WO2009088738A2/en active Application Filing
- 2008-12-22 AU AU2008346842A patent/AU2008346842A1/en not_active Abandoned
-
2010
- 2010-07-23 US US12/842,855 patent/US20100286023A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248771A1 (en) * | 2001-11-01 | 2004-12-09 | Giuseppe Raggi | Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
Non-Patent Citations (1)
Title |
---|
Layman The Journal of Nutrition (2003), Supplement, pages 261S-267S. * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090203606A1 (en) * | 2008-02-05 | 2009-08-13 | Wolfe Robert R | Systems for and Methods of use of Therapeutic Nutrition for the Management of Age-Associated and Age-Specific Health Conditions of the Elderly |
US9944681B2 (en) | 2012-03-26 | 2018-04-17 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
US8809259B2 (en) | 2012-03-26 | 2014-08-19 | Pronutria, Inc. | Charged nutritive proteins and methods |
US8822412B2 (en) | 2012-03-26 | 2014-09-02 | Pronutria, Inc. | Charged nutritive proteins and methods |
US9598474B2 (en) | 2012-03-26 | 2017-03-21 | Axcella Health, Inc. | Nutritive fragments, proteins and methods |
US9605040B2 (en) | 2012-03-26 | 2017-03-28 | Axcella Health Inc. | Nutritive proteins and methods |
US9611298B2 (en) | 2012-03-26 | 2017-04-04 | Axcella Health Inc. | Charged nutritive proteins and methods |
US9700071B2 (en) | 2012-03-26 | 2017-07-11 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
US10450350B2 (en) | 2012-03-26 | 2019-10-22 | Axcella Health Inc. | Charged nutritive proteins and methods |
WO2014138304A1 (en) * | 2013-03-08 | 2014-09-12 | Axiom Foods, Inc., | Rice protein supplements |
US9907331B2 (en) | 2013-03-08 | 2018-03-06 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
US10251415B2 (en) | 2013-03-08 | 2019-04-09 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
US11357824B2 (en) | 2013-09-25 | 2022-06-14 | Axcella Health Inc. | Nutritive polypeptides and formulations thereof, and methods of production and use thereof |
US11684074B2 (en) | 2017-05-12 | 2023-06-27 | Axiom Foods, Inc. | Rice products and systems and methods for making thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2231141A2 (en) | 2010-09-29 |
WO2009088738A3 (en) | 2009-10-08 |
CA2711809A1 (en) | 2009-07-16 |
MX2010007580A (en) | 2011-03-03 |
JP2011509293A (en) | 2011-03-24 |
US20090181903A1 (en) | 2009-07-16 |
US7790688B2 (en) | 2010-09-07 |
AU2008346842A1 (en) | 2009-07-16 |
WO2009088738A2 (en) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7790688B2 (en) | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly | |
US20080268038A1 (en) | Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength | |
US6903136B2 (en) | Food supplements containing 4-hydroxyisoleucine and creatine | |
EP3320895B1 (en) | Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine | |
US20120178672A1 (en) | Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis | |
US20100267831A1 (en) | Amino Acid-Containing Composition for Preventing or Remedying Decrease in the Skeletal Muscle of Aged People | |
US8703719B1 (en) | Method and composition for improved muscle performance | |
US11285124B2 (en) | Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma | |
US20100179089A1 (en) | Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly | |
US20040043442A1 (en) | Use of betaine in functional products having blood pressure lowering effects | |
EP2057905A1 (en) | Composition for moderating Triglyceride and Cholesterol Levels | |
US20090156647A1 (en) | Method for maintaining physiological pH levels during intensive physical exercise | |
US20080242727A1 (en) | Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass | |
US20090005320A1 (en) | Compositions comprising amino acid bicarbonate and methods of use thereof | |
US6703371B1 (en) | Preparations for reducing oxygen consumption during physical efforts | |
US11752112B2 (en) | Composition for stimulating muscle growth, repair, and maintenance | |
JP2000516937A (en) | Vitamin preparations that reduce oxygen consumption during exercise | |
US20210260039A1 (en) | Nutritional compositions for enhancement of muscle performance | |
Volek | Creatine supplementation and the strength athlete | |
JP2020031556A (en) | Muscle damage inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ENERGY LIGHT LLC, VIRGINIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:HEALTHSPAN SOLUTIONS, LLC;REEL/FRAME:028755/0232 Effective date: 20120314 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |